CORONAVIRUS: DIAGNOSIS AND THERAPY IN HUMANS

VolverGo back

Resultados 1322 results. LastUpdate Updated on 06/12/2021 [01:52:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 90 días/Published applications in the last 90 days



Page1/53 nextPage   results/page


NEGATIVE PRESSURE AEROSOL CONTAINMENT UNIT

Publication No.: US2021369399A1 02/12/2021

Applicant:

KIM TONY [US]
CALDERARA MARIO [US]

Absstract of: US2021369399A1

A device is disclosed for use by clinicians in medical and dental procedures to contain aerosols generated by patients with known or suspected respiratory pathogen (e.g., a virus such as COVID-19). The device of the invention (a negative pressure aerosol containment unit) may be in the form of a box with an opening at the bottom, the box configured to receive an attached HEPA filter and HVAC unit that creates a localized negative pressure area within the box. The device also may be in a non-rectilinear configuration.

traducir

Methods of Assigning a COVID Pathological Type and Compositions for Practicing the Same, and Methods of Treating a Subject for Chronic COVID-19

Publication No.: US2021373034A1 02/12/2021

Applicant:

INCELLDX INC [US]

Absstract of: US2021373034A1

Methods of assigning a COVID pathological type for a subject suffering from COVID-19 are provided. Aspects of the methods include assigning a COVID pathological type for the subject based on a determined quantitative, multiplex cytokine/chemokine panel in a test sample from the subject. Also provided are methods of treating a subject (e.g., a long hauler subject) for chronic COVID-19. Aspects of such methods include administering to the long hauler subject a CCR5/CCL5 interaction inhibitor to treat the long hauler subject. Also provided are compositions for use in practicing the methods. The methods and compositions find use in a variety of applications, including patient stratification, treatment and therapy determination and therapy response assessment.

traducir

PLASMONIC META-SURFACE BASED MOLECULAR SENSORS AND METHODS FOR MAKING AND USING THEM

Publication No.: US2021373009A1 02/12/2021

Applicant:

UNIV NORTH TEXAS [US]

Absstract of: US2021373009A1

A chiral metamaterial absorber modeled after the yin-yang symbol comprising: a top yin-yang shaped Au nanoparticles (YNPs); a PMMA layer; an Au backreflector; and a bottom glass layer. In alternative embodiments, provided are devices acting as sensors for detecting a nucleotide such as a cDNA and/or a protein such as a protein from a pathogen such as a bacteria or a virus, wherein the cDNA or protein can be derived from a Coronavirus, for example, a SARS CoV-2 or COVID-19 virus. In alternative embodiments, devices acting as sensors as provided herein can also be used to detect any protein for diagnostic or therapeutic purposes, wherein the protein can be derived from a blood or plasma sample, or a tissue sample, for example, a biopsy, from an individual in need thereof, for example, a human or an animal.

traducir

Method of Vaccination for SARS Virus

Publication No.: US2021369835A1 02/12/2021

Applicant:

FORREST SHAWNE [US]

Absstract of: US2021369835A1

A method of vaccination for severe acute respiratory syndrome (SARS) disease caused by at least one of SARS-CoV-1 virus and SARS-CoV-2 virus is achieved in inoculating a human with a specific vaccine composition. The vaccine composition includes a solution of salt water (H2O and NaCl), ascorbic acid (Vitamin C) and/or a ascorbic acid salt and/or citric acid and/or a citric acid salt and a source of the at least one of SARS-CoV-1 virus and SARS-CoV-2 virus. The vaccine composition is introduced into at least one of a lymph node, a hair follicle, and an ear canal of the human for purposes of vaccination for SARS disease.

traducir

Accelerated Treatment of COVID-19 and SAR's Type Viruses

Publication No.: US2021369719A1 02/12/2021

Applicant:

COHEN BINYOMIN A [US]
JONES MONICKA C [US]

Absstract of: US2021369719A1

The present invention provides a solution mixture of 1.8 to 3.7% hypertonic saline, 70 to 85% ethanol as solvent alternating with 10 milliliters 50 to 90% of 75 to 110 mg theobromine in a nebulized aerosol for inhalation by COVID-19 and SARS patients. Alternatively, theobromine may be infused alternating with inhaled nebulized exogenous pulmonary surfactant as replacement. For advanced COVID-19, SARS patients, the inhalation described above may be alternated with an intravenous solution of 1.8% to 2.2% hypertonic solution of theobromine as 450 mg to 650 mg in ethanol, twice daily.

traducir

ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USING THE SAME

Publication No.: US2021371504A1 02/12/2021

Applicant:

VIR BIOTECHNOLOGY INC [US]

US_2021261650_A1

Absstract of: US2021371504A1

The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.

traducir

ANTIMICROBIAL WEARABLE ARTICLE

Publication No.: US2021368901A1 02/12/2021

Applicant:

BIOSAFE GLOVES LLC [US]

Absstract of: US2021368901A1

Disclosed herein are articles (e.g., wearable articles, such as gloves and masks) comprising an antimicrobial material, and methods of manufacture thereof. In various embodiments, the antimicrobial material comprises dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium, or a salt thereof. In some embodiments, the antimicrobial article (e.g., a wearable article, such as a glove or mask) may have antiviral properties against coronavirus, such as SARS-CoV-2.

traducir

Antiviral Face Mask

Publication No.: US2021368890A1 02/12/2021

Applicant:

ARGENTUM MEDICAL LLC [US]

Absstract of: US2021368890A1

Disclosed herein are washable, reusable, antimicrobial and antiviral face masks and methods of their use for the reduction of transmission of infectious pathogens. Exemplary face masks are made of silver-coated material wherein activation of the silver from moisture in a user's breath kills pathogens. The disclosed face masks are useful in reducing, inhibiting or killing pathogens, such as SARS-CoV-2, that contact the face mask within 2 hours of continuous contact.

traducir

COMPOSITIONS AND METHODS FOR TREATING COVID-119 INFECTIONS

Publication No.: US2021369801A1 02/12/2021

Applicant:

APIQUESTUSA INC [US]

Absstract of: US2021369801A1

The present disclosure relates to compositions and methods for treating a subject having a COVID-19 infection. The present disclosure relates to the use of Dichrostachys glomerata extract as a medicament for the treatment of COVID-19 infections.

traducir

Use of an N-substituted pyridyl benzisoselazolone compound

Publication No.: US2021369696A1 02/12/2021

Applicant:

UNIV SHANGHAI TECH [CN]

WO_2021169957_A1

Absstract of: US2021369696A1

Disclosed is a use of an N-substituted pyridyl benzisoselazolone compound. The use is particularly a use in the preparation of a medicament for treating and/or preventing a disease caused by coronavirus. The present disclosure surprisingly found that the N-substituted pyridyl benzisoselazolone compound, such as ebselen, can significantly inhibit the activity of the main protease of a coronavirus and the intracellular replication capability of SARS-CoV-2, which can be used for treating a disease caused by coronavirus.

traducir

VITAMIN D AS AN IMMUNE MODULATOR TO PREVENT IMMUNE-RELATED COMPLICATION FROM COVID-19 INFECTION

Publication No.: US2021369741A1 02/12/2021

Applicant:

UNIV NORTHWESTERN [US]
UNIV CASE WESTERN RESERVE [US]
UNIV COLORADO REGENTS [US]

Absstract of: US2021369741A1

Disclosed herein are methods and compositions useful in reducing inflammation, reducing inflammatory exudates, enhancing epithelial tissue generation or regeneration, and/or reducing mean pulmonary artery pressure in the lungs of a subject in need thereof. In particular, the compositions comprise vitamin D, an analog, or metabolite thereof, and the methods include administering the composition to a subject in need thereof. In some embodiments, the subject is suffering from an infection, such as a viral infection, which affects the lungs. In some embodiments, the viral infection comprises SARS-CoV-2.

traducir

METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION

Publication No.: US2021369680A1 02/12/2021

Applicant:

T3D THERAPEUTICS INC [US]

Absstract of: US2021369680A1

This disclosure describes the use of indane acetic acid derivatives which are PPAR agonists, including PPAR delta, PPAR gamma, and dual PPAR delta and gamma agonists, and which penetrate the blood brain barrier to achieve effective brain to plasma drug levels at non-toxic doses, for the treatment of betacoronavirus diseases, such as COVID-19 and COVID-19 related co-morbid diseases, including Acute Respiratory Distress and CNS disorders, such as delirium and cognitive impairment.

traducir

Integrated COVID-19 Strategies

Publication No.: US2021369811A1 02/12/2021

Applicant:

MANYAK DAVID M [US]

Absstract of: US2021369811A1

This disclosure provides for the application of a multi-disciplinary analysis of information sources to draw novel conclusions that result in new methods to diagnose, prevent or treat COVID-19. COVID-19 appears to be an extremely complex disease, encompassing three critical aspects at least: a viral infection, an immune system disorder, and a cardiovascular/pulmonary/renal disease with significant coagulation system dysregulation. This disclosure principally focuses on modes and sites of infection of the SARS COV-2 virus and the role of lectins, the lectin complement pathway, coagulation system dysfunction, related genetic polymorphisms, trypsin-like serine proteases, interferon stimulation of the innate immune system, and other factors in the disease process. Corresponding methods to address the COVID-19 pandemic are provided.

traducir

LATERAL FLOW DETECTION DEVICE FOR DETECTING A CORONAVIRUS BY IMMUNOASSAY

Publication No.: US2021373018A1 02/12/2021

Applicant:

HANGZHOU BIOTEST BIOTECH CO LTD [CN]

Absstract of: US2021373018A1

The present invention provides a lateral flow test device for detecting a coronavirus antibody by immunoassay; the test device includes three lateral flow test strips; a first test strip is directed to the antibody detection of a N full-length protein and/or an S full-length protein antigens/antigen; and a second test strip is directed to the antibody detection of an S-RBD-site protein antigen, and both of the first strip and the second strip are combined to detect novel coronavirus IgG and IgM antibodies, which can practically reduce the possibility of missing detection and wrong detection; further, a third test strip is directed to the detection of a neutralizing antibody at an S-RBD site to rapidly detect the neutralizing antibody having protection effect, thus further helping the prevention of missing detection and helping patients to perform self-detection and judge the situations of recovery, or vaccine immunity.

traducir

SYSTEMS AND PROCESSES TO SCREEN FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) OF 2019 (COVID-19)

Publication No.: US2021373020A1 02/12/2021

Applicant:

BATTELLE MEMORIAL INSTITUTE [US]

US_2021373019_A1

Absstract of: US2021373020A1

Alternative antibodies to screen for SARS-CoV-2 are disclosed. One alternative antibody is Mouse Species Coronavirus (COVID-19, MERS, and SARS-CoV NP) Antibody, Catalog Number HM1056 (“E3-Antibody” or “E3”), from EastCoast Bio, Inc., PO Box 489, North Berwick, Me. 03906, USA (“EastCoast Bio”). Another alternative antibody is a combination of the E3-Antibody and Mouse Species Coronavirus (COVID-19, MERS, and SARS-CoV NP) Antibody, Catalog Number HM1057 (“E1-Antibody” or “E1”), from EastCoast Bio (the combination of the E1-Antibody and the E3-Antibody is designated as “E1/E3-Antibody” or simply “E1/E3”). Yet another alternative antibody is a combination of Mouse Species Anti-SARS-CoV-2 NP mAb, clone 4B21, Catalog Number CABT-CS027 (“C4-Antibody” or “C4”), from Creative Diagnostics, 45-1 Ramsey Road, Shirley, N.Y. 11967, USA (“Creative Diagnostics”), and Mouse Species Anti-SARS-CoV-2 NP mAb, clone 7G21, Catalog Number CABT-CS026 (“C5-Antibody” or “C5”), also from Creative Diagnostics (the combination of the C4-Antibody and the C5-Antibody is designated as “C4/C5-Antibody” or simply “C4/C5”).

traducir

SYSTEMS AND METHODS FOR DETECTION OF LOW-COPY NUMBER NUCLEIC ACIDS

Publication No.: US2021371941A1 02/12/2021

Applicant:

DIMSOSKI PERO [US]

Absstract of: US2021371941A1

Disclosed are compositions, methods, and systems for genetic identification and detection of low-copy number nucleic acids, and provides method, compositions, and kits useful for this purpose. The methods of the invention can be used to detect in a given sample the presence of low-copy number of nucleic acids (e.g., DNA or RNA) of various microorganisms, including SARS-COV-2.

traducir

REAL-TIME MONITORING OF COVID-19 PROGRESS USING MAGNETIC SENSING AND MACHINE LEARNING

Publication No.: US2021369137A1 02/12/2021

Applicant:

UNIV SOUTH FLORIDA [US]

Absstract of: US2021369137A1

A breathing monitor that includes a contactless sensor that uses magneto-LC resonance technology is provided. The breathing monitor collects breathing data from a patient that indicates a breathing pattern of the patient. A model trained using machine learning using breathing patterns collected from patients known to have different stages of COVID-19 is used to process the collected breathing data and to determine whether the patient has COVID-19. The model further determines the stage of COVID-19. The breathing monitor can identify likely COVID-19 infections faster than existing tests and requires no contact between the patient and a medical professional, which is an improvement over existing COVID-19 detection technologies.

traducir

METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKING GALECTIN-3

Publication No.: US2021371533A1 02/12/2021

Applicant:

TRUEBINDING INC [US]

Absstract of: US2021371533A1

Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.

traducir

SYSTEMS AND PROCESSES TO SCREEN FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) OF 2019 (COVID-19)

Publication No.: US2021373019A1 02/12/2021

Applicant:

BATTELLE MEMORIAL INSTITUTE [US]

US_2021373020_A1

Absstract of: US2021373019A1

Systems and processes to screen for SARS-CoV-2, which includes a process that uses an alternative antibody for ELISA. The alternative antibody is an alternative to a mouse antibody, thereby expanding the ability to test for COVID-19 using non-human antibodies.

traducir

NEUTRALIZING ANTIBODIES AGAINST SARS-RELATED CORONAVIRUS

Publication No.: US2021371503A1 02/12/2021

Applicant:

UNIV OF COLOGNE [DE]
PHILIPPS UNIV MARBURG [DE]

Absstract of: US2021371503A1

The present invention relates to antibodies or antigen-binding fragments thereof against SARS-related coronavirus, a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof, a kit comprising such antibodies or antigen-binding fragments thereof. The present invention also relates to the antibodies or antigen-binding fragments thereof, the pharmaceutical composition, and the kit, for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus.

traducir

SURVEILLANCE METHOD TO SCREEN ASYMPTOMATIC ESSENTIAL WORKERS FOR EXHALATION OF SARS-COV-2

Publication No.: US2021371905A1 02/12/2021

Applicant:

UNIV VANDERBILT [US]

Absstract of: US2021371905A1

Disclosed herein is a COVID-19 surveillance method for detecting exhaled virions trapped within used face masks. This is a surveillance and warning system for identifying asymptomatic and pre-symptomatic individuals, particularly essential workers required to wear masks while at work. This can include healthcare workers, first responders, nursing home personnel, postal workers, or employees at meat packing and other production facilities. A piece of filter paper can be added to the inside of a standard face mask, which can be removed at the end of a shift. Mask inserts from a group of employees can be pooled and tested using standard RT-PCR for virions collected during normal exhalation over the time the mask is worn. As envisioned, if the group test is positive, additional follow-up or contact tracing could be initiated to identify the individual or individuals requiring treatment or quarantine.

traducir

METHODS FOR EXPANDING SARS-COV2-ANTIGEN-SPECIFIC T CELLS, COMPOSITIONS AND USES RELATED THERETO

Publication No.: US2021371822A1 02/12/2021

Applicant:

UNIV SOUTHERN CALIFORNIA [US]

Absstract of: US2021371822A1

Provided herein are methods for preparing and characterizing SARS-co2 antigen specific immune cell cultures and preparations and methods of using the same in adoptive immunotherapy for cancer, infections and immune disorders. Also, provided are compositions and methods for generating immune cells expressing synthetic antigen binding receptors targeting SARS-cov2 and methods of use of these cells for the treatment and prevention of COVID-19. Also provided are compositions and methods for determining immune response to SARs-cov2 in a subject, detecting SARS-cov2, measuring cytotoxicity induced by SARS-cov2, and detecting the expression and cytotoxicity of synthetic antigen binding receptors targeting SARS-cov2.

traducir

FUSION PROTEINS COMPRISING THE SARS-COV-2 3CLPRO CATALYTIC DOMAIN AND THEIR USES FOR SCREENING ANTI-SARS-COV-2 AGENTS

Publication No.: EP3916088A1 01/12/2021

Applicant:

INST NAT SANTE RECH MED [FR]
UNIV DE LA REUNION SAINT DENIS [FR]
INSTITUT DE RECH POUR LE DEVELOPPEMENT IRD [FR]
CENTRE NAT RECH SCIENT [FR]

Absstract of: EP3916088A1

In late December 2019, a new betacoronavirus SARS-CoV-2 has emerged in Wuhan China. The World Health Organization has named the severe pneumonia caused by this new coronavirus COVID-19 (for Corona Virus Disease 2019, WHO, 2020). To fight against the COVID-19 pandemic in a long term, in addition to the containment measures implemented in many countries, several projects have been launched around the world to understand the viral evolution and the pathophysiological consequences of the infection in order to identify therapeutic targets and to implement innovative therapies. In particular, the 3C-like proteinase (3CLpro) of the severe acute respiratory syndrome coronavirus (SARS-CoV) plays a vital role in virus maturation and is proposed to be a key target for drug design against SARS. The present invention relates to fusion proteins comprising the SARS-CoV-2 3CLpro catalytic domain and their uses for screening anti-SARS-Cov-2 agents.

traducir

TRANSMUCOSAL DOSAGE FORMS OF REMDESIVIR

Publication No.: EP3915547A1 01/12/2021

Applicant:

JUBILANT GENERICS LTD [IN]

Absstract of: EP3915547A1

Disclosed herein are the sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. The present invention also relates to a process for preparing sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. Compositions of remdesivir prepared as per present invention are able to increase bioavailability by avoiding first-pass metabolism. The compositions of remdesivir prepared as per present invention are useful in the treatment of viral infections including coronavirus infection (COVID-19). The compositions of remdesivir prepared as per present invention exhibit desired pharmaceutical technical attributes such as pH, assay, related substance, disintegration and dissolution.

traducir

TRANSMUCOSAL PHARMACEUTICAL COMPOSITIONS OF ANTIVIRAL DRUGS

Nº publicación: EP3915548A1 01/12/2021

Applicant:

JUBILANT GENERICS LTD [IN]

Absstract of: EP3915548A1

The present invention relates to the transmucosal dosage forms like sublingual pharmaceutical compositions comprising antiviral molecules like favipiravir, remdesivir, baloxavir marboxil, molnupiravir, besifovir, raltegravir, GS-441524, ravidasvir, and other antiviral drugs. The present invention also relates to methods for preparing these transmucosal pharmaceutical compositions. Compositions prepared as per the present invention are able to increase bioavailability by avoiding first-pass metabolism. The compositions prepared as per the present invention exhibit desired pharmaceutical technical attributes such as pH, assay, related substance, disintegration, and dissolution. The compositions prepared as per the present invention are useful in the treatment of viral infections including coronavirus infection (COVID-19).

traducir

Page1/53 nextPage results/page

punteroimgGo back